amphotericin B
E556051
Amphotericin B is a broad-spectrum antifungal medication primarily used to treat severe, systemic fungal infections.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Amphotericin B | 0 |
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
antifungal agent
ⓘ
medication ⓘ polyene antifungal drug ⓘ |
| canBeCombinedWith | flucytosine NERFINISHED ⓘ |
| combinedWithFlucytosineUsedFor | induction therapy of cryptococcal meningitis ⓘ |
| derivedFrom | Streptomyces nodosus NERFINISHED ⓘ |
| discoveredBy | Squibb Institute for Medical Research NERFINISHED ⓘ |
| hasAdverseEffect |
anemia
ⓘ
fever and chills ⓘ hypokalemia ⓘ infusion-related reactions ⓘ nephrotoxicity ⓘ |
| hasATCCode | J02AA01 ⓘ |
| hasBioavailability | very low oral bioavailability ⓘ |
| hasBlackBoxWarning | should be used primarily for progressive, potentially life-threatening fungal infections ⓘ |
| hasCASNumber | 1397-89-3 ⓘ |
| hasChemicalFormula | C47H73NO17 ⓘ |
| hasEffect |
causes leakage of intracellular contents of fungi
ⓘ
fungicidal or fungistatic depending on concentration and organism ⓘ |
| hasMechanismOfAction |
binds to ergosterol in fungal cell membranes
ⓘ
forms pores in fungal cell membranes ⓘ |
| hasMolarMass | 924.08 g/mol ⓘ |
| hasProteinBinding | >90% ⓘ |
| hasRouteOfAdministration |
intrathecal
ⓘ
intravenous ⓘ oral ⓘ topical ⓘ |
| hasSpectrumIncludes |
Aspergillus species
ⓘ
Blastomyces dermatitidis NERFINISHED ⓘ Candida species NERFINISHED ⓘ Coccidioides species NERFINISHED ⓘ Cryptococcus neoformans NERFINISHED ⓘ Histoplasma capsulatum NERFINISHED ⓘ Mucorales NERFINISHED ⓘ |
| isAdministeredFor | severe systemic mycoses ⓘ |
| isBroadSpectrumAgainst | fungi ⓘ |
| isFormulatedAs |
colloidal dispersion amphotericin B
ⓘ
conventional deoxycholate formulation ⓘ lipid complex amphotericin B ⓘ liposomal amphotericin B ⓘ |
| isListedOn | World Health Organization Model List of Essential Medicines NERFINISHED ⓘ |
| isNotAbsorbedFrom | gastrointestinal tract when given orally ⓘ |
| isOftenUsedAs | initial induction therapy for serious fungal infections ⓘ |
| liposomalFormulationsHaveProperty | reduced nephrotoxicity compared with conventional formulation ⓘ |
| usedForTreatmentOf |
aspergillosis
ⓘ
cryptococcal meningitis ⓘ invasive candidiasis ⓘ mucormycosis ⓘ systemic fungal infections ⓘ visceral leishmaniasis ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.